Cargando…
An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
BACKGROUND: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and di...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107951/ https://www.ncbi.nlm.nih.gov/pubmed/24990477 http://dx.doi.org/10.1186/1471-2334-14-359 |
_version_ | 1782327681450246144 |
---|---|
author | Lu, Haifeng Zhang, Chunxia Qian, Guirong Hu, Xinjun Zhang, Hua Chen, Chunlei Liang, Weifeng Gao, Hainv Yang, Yunmei Li, Lanjuan |
author_facet | Lu, Haifeng Zhang, Chunxia Qian, Guirong Hu, Xinjun Zhang, Hua Chen, Chunlei Liang, Weifeng Gao, Hainv Yang, Yunmei Li, Lanjuan |
author_sort | Lu, Haifeng |
collection | PubMed |
description | BACKGROUND: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and reducing secondary infections. METHODS: Comprehensive therapies were dependent on the individual clinical situation of subjects, and were divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage, and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE) were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens. RESULTS: Different antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of communities under the continual suppression of the same antibiotics, and significant changes when new antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail in these patients. CONCLUSIONS: Elderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration strategies for secondary infection were unsatisfactory in elderly and critically ill patients. |
format | Online Article Text |
id | pubmed-4107951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41079512014-07-24 An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection Lu, Haifeng Zhang, Chunxia Qian, Guirong Hu, Xinjun Zhang, Hua Chen, Chunlei Liang, Weifeng Gao, Hainv Yang, Yunmei Li, Lanjuan BMC Infect Dis Research Article BACKGROUND: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and reducing secondary infections. METHODS: Comprehensive therapies were dependent on the individual clinical situation of subjects, and were divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage, and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE) were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens. RESULTS: Different antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of communities under the continual suppression of the same antibiotics, and significant changes when new antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail in these patients. CONCLUSIONS: Elderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration strategies for secondary infection were unsatisfactory in elderly and critically ill patients. BioMed Central 2014-07-02 /pmc/articles/PMC4107951/ /pubmed/24990477 http://dx.doi.org/10.1186/1471-2334-14-359 Text en Copyright © 2014 Lu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Article Lu, Haifeng Zhang, Chunxia Qian, Guirong Hu, Xinjun Zhang, Hua Chen, Chunlei Liang, Weifeng Gao, Hainv Yang, Yunmei Li, Lanjuan An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection |
title | An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection |
title_full | An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection |
title_fullStr | An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection |
title_full_unstemmed | An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection |
title_short | An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection |
title_sort | analysis of microbiota-targeted therapies in patients with avian influenza virus subtype h7n9 infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107951/ https://www.ncbi.nlm.nih.gov/pubmed/24990477 http://dx.doi.org/10.1186/1471-2334-14-359 |
work_keys_str_mv | AT luhaifeng ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT zhangchunxia ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT qianguirong ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT huxinjun ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT zhanghua ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT chenchunlei ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT liangweifeng ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT gaohainv ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT yangyunmei ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT lilanjuan ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT luhaifeng analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT zhangchunxia analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT qianguirong analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT huxinjun analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT zhanghua analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT chenchunlei analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT liangweifeng analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT gaohainv analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT yangyunmei analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection AT lilanjuan analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection |